Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Stroke. 2017 Mar 21;48(5):1420–1423. doi: 10.1161/STROKEAHA.116.015713

Figure 2. AAV9-sFLT1 IV reduces DI in bAVM in Model 1 (R26CreER;Eng2f/2f).

Figure 2

(A) Representative CD31 antibody-stained brain images. White arrows: Abnormal vessels. White stars: Enlarged abnormal vessel lumens. Scale bar=100 μm. (C) DI quantifications. (D) Vessel density quantifications. GFP-treated group: N=11. sFLT1-treated group: N=12. *: p=0.011.